Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-28 DOI:10.1080/14796694.2025.2481022

Reginald Villacorta, Shannon Gallagher-Colombo, Armin Lahiji, Sky Myers, Jonathon Briggs, Angaja Phalguni

{"title":"Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites.","authors":"Reginald Villacorta, Shannon Gallagher-Colombo, Armin Lahiji, Sky Myers, Jonathon Briggs, Angaja Phalguni","doi":"10.1080/14796694.2025.2481022","DOIUrl":null,"url":null,"abstract":"Aims: This study aimed to expand on existing systematic literature reviews (SLRs) by assessing the prevalence of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive mutations across solid tumors in adult U.S populations. It further evaluated incidence, testing, treatment, mortality, and progression rates by tumor type, extending evidence through 2023.Materials & methods: A SLR was conducted following Cochrane and PRISMA guidelines, with searches across Ovid Embase, Ovid MEDLINE, and Cochrane Library databases for studies published from 2013 to August 2023. Eligibility criteria included studies on NTRK fusion-positive tumors in patients aged ≥12 years. Data were extracted and assessed using the Newcastle-Ottawa Scale and JBI checklist.Results: This SLR identified 160 studies, reporting NTRK fusion prevalence ranging from 0.03% to 0.70% across solid tumors. TRK inhibitors, particularly larotrectinib and entrectinib, were commonly used treatments. Prevalence varied significantly by cancer type, being higher in rarer cancers, such as papillary thyroid carcinoma (up to 21.4%).Conclusions: NTRK fusions are rare, with wide prevalence variability among cancer types. The findings highlight the need for standardized diagnostic methods and larger real-world studies to improve prevalence estimates and assess the impact of NTRK fusions on outcomes, ultimately aiding in the optimization of targeted treatments for affected patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1403-1415"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051583/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2481022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study aimed to expand on existing systematic literature reviews (SLRs) by assessing the prevalence of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive mutations across solid tumors in adult U.S populations. It further evaluated incidence, testing, treatment, mortality, and progression rates by tumor type, extending evidence through 2023.

Materials & methods: A SLR was conducted following Cochrane and PRISMA guidelines, with searches across Ovid Embase, Ovid MEDLINE, and Cochrane Library databases for studies published from 2013 to August 2023. Eligibility criteria included studies on NTRK fusion-positive tumors in patients aged ≥12 years. Data were extracted and assessed using the Newcastle-Ottawa Scale and JBI checklist.

Results: This SLR identified 160 studies, reporting NTRK fusion prevalence ranging from 0.03% to 0.70% across solid tumors. TRK inhibitors, particularly larotrectinib and entrectinib, were commonly used treatments. Prevalence varied significantly by cancer type, being higher in rarer cancers, such as papillary thyroid carcinoma (up to 21.4%).

Conclusions: NTRK fusions are rare, with wide prevalence variability among cancer types. The findings highlight the need for standardized diagnostic methods and larger real-world studies to improve prevalence estimates and assess the impact of NTRK fusions on outcomes, ultimately aiding in the optimization of targeted treatments for affected patients.

查看原文本刊更多论文

神经营养酪氨酸受体激酶阳性实体瘤部位的流行病学系统文献综述。

目的：本研究旨在通过评估美国成年人群实体瘤中神经营养酪氨酸受体激酶（NTRK）融合阳性突变的患病率，扩展现有的系统文献综述（SLRs）。它进一步评估了肿瘤类型的发病率、检测、治疗、死亡率和进展率，将证据延长到2023年。材料与方法：根据Cochrane和PRISMA指南进行单反研究，检索Ovid Embase、Ovid MEDLINE和Cochrane Library数据库，检索2013年至2023年8月发表的研究。入选标准包括年龄≥12岁的NTRK融合阳性肿瘤患者。数据提取和评估使用纽卡斯尔-渥太华量表和JBI检查表。结果：该SLR鉴定了160项研究，报告了NTRK融合在实体肿瘤中的患病率从0.03%到0.70%不等。TRK抑制剂，特别是larorectinib和entrectinib，是常用的治疗方法。不同癌症类型的患病率差异很大，在罕见的癌症中患病率较高，如甲状腺乳头状癌（高达21.4%）。结论：NTRK融合是罕见的，在不同的癌症类型中具有广泛的患病率差异。研究结果强调需要标准化的诊断方法和更大规模的现实世界研究，以改善患病率估计和评估NTRK融合对结果的影响，最终帮助优化受影响患者的靶向治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.